Durvalumab consolidation after chemoradiotherapy in unresectable stage III non-small cell lung cancer: A real-world experience from the Australian subset of PACIFIC-R
- Author(s)
- Markman, B; Kao, S; Pavlakis, N; Bray, V; Packer, L; Siva, S;
- Journal Title
- Cancer Treatment and Research Communications
- Publication Type
- Research article
- Abstract
- MICROABSTRACT: Australian subset of the multicentric PACIFIC-R study (NCT03798535) in patients with unresectable, stage III non-small cell lung cancer without progression following chemoradiotherapy, found a median progression-free survival of 22.4 months (95% confidence interval, 17.5 to 30.8) confirming clinical benefit of durvalumab consolidation post-chemoradiotherapy in the real-world setting. INTRODUCTION: The Phase 3 PACIFIC trial established post-chemoradiotherapy (CRT) durvalumab consolidation as standard treatment for patients with unresectable, stage III non-small cell lung cancer (NSCLC). We present the results from the Australian subset of the multicentric PACIFIC-R study (NCT03798535) assessing the effectiveness of durvalumab in the real-world setting. PATIENTS AND METHODS: Patients with unresectable, stage III NSCLC without progression following CRT, receiving at least 1 dose of durvalumab (10 mg/kg intravenously, every 2 weeks) through an early access program (EAP) between September 2017 and December 2019, were enrolled. Primary endpoints, progression-free survival (PFS) and overall survival (OS) were analyzed by Kaplan-Meier method. RESULTS: AS OF FEBRUARY 7, 2022, 165 PATIENTS (MEDIAN AGE: 67.0 years) with a median follow-up of 34.7 months were enrolled. Most received last radiation ≥42 days before durvalumab initiation (126, 79.2%) at a dose of 54 to 60 Gy (141, 88.7%). Median PFS was 22.4 months (95% confidence interval [CI], 17.5 to 30.8). The 3-year PFS and OS rates were 38.9% (95% CI, 31.0 to 46.7) and 59.1% (95% CI, 51.2 to 66.2). Pneumonitis was the most frequent adverse events of special interest (27, 16.4%); which led to treatment discontinuation in 19 (11.5%) patients. CONCLUSION: The real-world results from the Australian PACIFIC-R subset confirm translation of the clinical benefit of post-CRT durvalumab consolidation in the pivotal PACIFIC trial to the real-world setting, showing favorable survival outcomes, irrespective of delays in durvalumab initiation post-radiation.
- Publisher
- Elsevier
- Keywords
- Australia; Durvalumab; Pacific-r; Progression-free survival; Unresectable stage III NSCLC
- Department(s)
- Radiation Oncology
- Publisher's Version
- https://doi.org/10.1016/j.ctarc.2025.100929
- Open Access at Publisher's Site
https://doi.org/10.1016/j.ctarc.2025.100929- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-06-02 07:40:50
Last Modified: 2025-06-02 07:41:12